Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023)
Prokidney (PROK) reported Long-Term Deferred Tax of $1.5 million for Q4 2023, down 15.12% year-over-year from $1.8 million in Q4 2022, and down 15.12% on a QoQ basis from $1.8 million in Q4 2022.
Prokidney (PROK) has 2 years of Long-Term Deferred Tax data on file, last reported at $1.5 million in Q4 2023.
- Quarterly Long-Term Deferred Tax fell 15.12% year-over-year to $1.5 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.5 million (down 15.12% YoY) and the FY2023 annual result came in at $1.5 million, down 15.12% from the prior year.
- Long-Term Deferred Tax declined to $1.5 million in Q4 2023 per PROK's latest filing, from $1.8 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $1.8 million in Q4 2022 and bottomed at $1.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.49 Mn |
| Dec 31, 2022 | 1.76 Mn |